Real-world evidence on fremanezumab for migraine treatment in Japan: a retrospective analysis

被引：0
|
作者：
Takizawa, T. [1 ]
Ohtani, S. [1 ,2 ]
Watanabe, N. [1 ]
Ihara, K. [1 ]
Takahashi, N. [1 ]
Miyazaki, N. [3 ]
Ishizuchi, K. [1 ]
Takemura, R. [3 ]
Hori, S. [2 ]
Nakahara, J. [1 ]
机构：
[1] Keio Univ, Sch Med, Dept Neurol, Tokyo, Japan
[2] Keio Univ, Fac Pharm, Div Drug Informat, Tokyo, Japan
[3] Keio Univ Hosp, Biostat Unit, Clin & Translat Res Ctr, Tokyo, Japan
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P254
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yim, E.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
  • [12] Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study
    Gladstone, Jonathan
    Chhibber, Sameer
    Minhas, Jagdeep
    Neish, Calum S.
    Power, G. Sarah
    Lan, Zhiyi
    Rochdi, Driss
    Lanthier-Martel, Jessica
    Bastien, Natacha
    HEADACHE, 2022, 62 (01): : 78 - 88
  • [13] Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
    McAllister, Peter
    Lamerato, Lois
    Krasenbaum, Lynda J.
    Cohen, Joshua M.
    Tangirala, Krishna
    Thompson, Stephen
    Driessen, Maurice
    Casciano, Julian
    Dotiwala, Zenobia
    Mauskop, Alexander
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [14] Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
    Peter McAllister
    Lois Lamerato
    Lynda J. Krasenbaum
    Joshua M. Cohen
    Krishna Tangirala
    Stephen Thompson
    Maurice Driessen
    Julian Casciano
    Zenobia Dotiwala
    Alexander Mauskop
    The Journal of Headache and Pain, 2021, 22
  • [15] A retrospective real world evaluation of Fremanezumab (Ajovy) in the management of refractory chronic migraine
    Ghadiri-Sani, Mona
    Broadhurst, Sarah
    Perry, Loouise
    Stockley, Angela M.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 70 - 70
  • [16] Analysis of Treatment Change of Acute Prescription Migraine Medications Using Real-World Evidence
    Lipton, R. B.
    Silberstein, S. D.
    Baradaran, S.
    Shewale, A. R.
    Cotton, S.
    Jackson, J.
    Viswanathan, H. N.
    HEADACHE, 2019, 59 : 83 - 83
  • [17] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    HEADACHE, 2021, 61 : 71 - 72
  • [18] REAL-WORLD REDUCTIONS IN ACUTE MEDICATION USE FOR PATIENTS WITH MIGRAINE INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Krasenbaum, L. J.
    Driessen, M. T.
    Seminerio, M. J.
    DiEgidio, R.
    Tian, M.
    VALUE IN HEALTH, 2022, 25 (07) : S325 - S325
  • [19] Real-world burden and treatment of chronic rhinosinusitis in Japan: A retrospective claims database analysis
    Yoshikawa, Mamoru
    Sunaga, Yoshinori
    Koshiba, Ryuji
    Inukai, Miho
    Takeuchi, Makiko
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2023, 8 (02): : 346 - 356
  • [20] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
12345